Lamictal XR (Lamotrigine) Patent Expiration, LOE Window & CMS Spending

Lamictal XR (Lamotrigine) by GSK: FDA Orange Book LOE 2029-01-07, 10 AB generics, $81.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGSK
FDA Application & PathwayN022115 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2029-01-07
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors10
2024 CMS Total Public Spend$81.9M
2024 Medicare Part D Spend$48.3M
2024 Medicaid Spend$33.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.